2 Min Read
FILE PHOTO: The logo of the Carlyle Group is displayed at the company s office in Tokyo, Japan October 17, 2018. REUTERS/Issei Kato
HONG KONG (Reuters) - Chinese biotech company Abbisko Therapeutics Co has raised $123 million from more than a dozen investors, including Carlyle Group and Warburg Pincus, in its latest funding round, the company said on Friday.
Abbisko said in a news release that Carlyle led the latest fundraising with Warburg, OrbiMed, Lake Bleu Capital, and an unnamed Boston-based investor as the joint leading investors.
Other investors include Janchor Partners, Sage Partners, SHC and Greater Bay Area Homeland Development Fund.